Cytomics Pharmaceuticals

About Cytomics Pharmaceuticals

Cytomics Pharmaceuticals was a French biopharmaceutical company focused on drug development. The company secured $11.9 million in a Series B funding round on March 2, 2006. This financing was led by institutional investors Truffle Capital and Edmond de Rothschild.

The company was founded by Dr. François-Xavier Frapaise and Stanislas Veillet. Dr. Frapaise has an extensive background of over 40 years in the international pharmaceutical industry, holding various executive positions such as CEO, CSO, and CMO at major companies including Sanofi, Bayer, Merck, and Abbott. He earned his M.D. from the University of Paris and also holds degrees in statistics and business from INSEAD. His career has been marked by a significant focus on drug development from phase I to IV and deep expertise in the field of biosimilars.

Cytomics Pharmaceuticals' core business revolved around the development of therapeutic proteins for treating cancer and autoimmune disorders. The company's approach challenged the conventional clinical development model for biosimilars, which often involves expensive and lengthy phase 3 trials. Instead, Cytomics advocated for a model that relies on a strong chemistry, manufacturing, and controls (CMC) package combined with comprehensive phase 1 studies. This methodology was designed to establish biosimilarity with greater efficiency, with any remaining uncertainty addressed through post-approval long-term follow-up studies and real-world data, aiming to reduce the financial and operational burden of large-scale clinical trials.